Two people wearing blue gloves and lab coats examine a small glass vial in a laboratory setting, with one person holding the vial up to the light and the other pointing at it.

PREPAREDNESS TODAY, SAFER TOMORROW.

Countermeasures season 4 is out now - follow along as we look back at public health crises and bioterrorism events throughout history.

Listen and Subscribe

The New Way Forward

Who we protect will not change, but how we protect them will. Emergent is leading the new way forward for public health.

Learn more

Capabilities

We are a leading public health company that delivers protective and life-saving solutions to communities around the world.

  • We offer commercialized products that address endemic public health threats such as the opioid epidemic.

  • We specialize in developing, manufacturing, and supplying medical countermeasures for national security and public health preparedness.

  • We leverage our specialized in-house capabilities to support biopharma innovators, governments and non-government organizations with their development and manufacturing needs. ​

A person wearing a helmet and backpack stands with a bicycle, talking to a smiling woman sitting on a park bench, with city buildings and green trees in the background.

At Emergent, our mission is to protect and save lives.

View our 2025 Annual Report

Emergent BioSolutions to Participate in Jefferies Global Healthcare Conference

GAITHERSBURG, Md., November 10, 2026 (BUSINESS WIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the Jefferies Global Healthcare Conference in London, November 16-19, 2026.
Read More

Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War

GAITHERSBURG, Md., November 4, 2026 (BUSINESS WIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has received a modification exercising an option period under its existing delivery order valued at up to $22.3 million to supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War (DoW). The first delivery, which is valued at approximately $7.4 million, will begin this year, and remaining deliveries are expected in 2027.
Read More

Emergent Biosolutions Reports Third Quarter 2026 Financial Results

GAITHERSBURG, Md., November 2, 2026 (BUSINESS WIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the third quarter ended September 30, 2026.
Read More
READ ALL NEWS